Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept

Nirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne · 2024

Read Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept by Nirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11541223.txt.

Description

PurposeThe inclusion of ranibizumab biosimilars into National Health Service England commissioning recommendations published in 2022 created a need for expert guidance to optimize treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) who otherwise may not have received first-line ranibizumab.

Catalog record

CREATORNirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11541223

Browse the full library · About the Tower of Babel